Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
ase 2clinical development for multiple tumor types. The Company also ...KERYX CONTACT: ...Lauren Fischer ...Director - Investor Relations ...Keryx Biopharmaceuticals Inc. ...
Date:6/24/2008
ase 2
clinical development for multiple tumor types. The Company also has an
in-licensing and acquisition program designed to identify and acquire
additional drug candidates. Keryx is headquartered in New York City.
KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com
'/>"/>SOURCE Keryx Biopharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results2.
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT3.
Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference4.
Keryx Biopharmaceuticals Receives Nasdaq Notification5.
Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan6.
Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference7.
Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint8.
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results9.
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST10.
Keryx Biopharmaceuticals Announces Additions to Management Team11.
Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations